Amgen Inc. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Amgen Inc. with three other
companies in this sector in the United States:
Biogen Inc
(2018
sales of $13.45 billion
of which 81%
was Product revenues, net),
Gilead Sciences, Inc.
($22.13 billion
of which 22%
was Ranexa & Other), and
Grifols SA
($5.29 billion
of which 78%
was Bioscience).
Sales Analysis.
Amgen Inc. reported sales of $23.75 billion
for the
year ending
December of 2018.
This
represents
an
increase of 3.9%
versus 2017, when the company's sales were $22.85 billion.